Background: Swallowing problems are common in Parkinson's Disease (PD) and aspiration pneumonia is the leading cause of death. Deep brain stimulation (DBS) surgery can successfully manage the motor symptoms of PD when pharmacological management begins to fail. Before DBS it is important to identify baseline dysfunction, but no consensus regarding swallowing screening exists.
Objectives: This study was undertaken to: 1) identify the prevalence of dysphagia prior to DBS; and 2) determine if screening measures or other characteristics were predictive for reduced airway protection.
Methods: A standardized protocol was performed for 137 consecutive patients with idiopathic PD and no confounding medical conditions, including those referred for work-up of dysphagia (n = 57) and those prior to DBS (n = 80). Three validated screening measures were completed before videofluoroscopic evaluation.
Results: On videofluoroscopy, there were significant differences in reduced airway protection by group (dysphagia group: 44 %; pre-DBS group: 21 %). Aspiration also differed by group (dysphagia group: 18 %; pre-DBS group: 8 %) although not significantly. Although there were significant between-group differences, none of the screening measures was predictive of reduced airway protection or aspiration in the sample overall. Male gender, previous videofluoroscopic evaluation, history of pneumonia, and previous DBS surgery were associated with increased aspiration-risk. Age also showed a modest correlation.
Conclusions: Dysphagia is not uncommon prior to DBS. No screening measure accurately predicted reduced airway protection on videofluoroscopy. Abnormal findings on clinical assessment prior to DBS, particularly in patients that are older, male, or have a history of pneumonia, may identify individuals requiring an objective dysphagia evaluation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.clineuro.2021.106587 | DOI Listing |
J Allergy Clin Immunol Glob
February 2025
Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, Hong Kong.
Background: Hereditary angioedema (HAE) is a rare genetic disorder with potentially life-threatening consequences, traditionally diagnosed by conventional laboratory methods that can be resource intensive and inconvenient. Incorporating dried blood spot (DBS) tests may be a promising alternative for diagnosing HAE and family screening.
Objective: This study aimed to validate DBS with conventional laboratory assays among confirmed C1 esterase inhibitor (C1-INH) HAE patients and assess the utility of DBS in a Screening Programme Providing Outreach for Testing Hereditary Angioedema (SPPOT-HAE).
Introduction: Limited treatments for Mild Cognitive Impairment (MCI) highlight the need to explore innovations including Deep Brain Stimulation (DBS), with patient perspectives key to ethical protocol development.
Methods: Seven MCI patients and four care partners were interviewed (Feb 2023-Jan 2024) about daily MCI challenges, desired treatment outcomes, and views on DBS. Thematic analysis following COREQ guidelines identified key themes.
Pract Radiat Oncol
December 2024
Department of Radiation Oncology, Willis Knighton Cancer Center, 2600 Kings Highway, Shreveport, Louisiana, USA 71103 &, Department of Clinical Research, University of Jamestown, Fargo, ND, USA. Electronic address:
Purpose: Motion management presents a significant challenge in thoracic stereotactic ablative radiotherapy (SABR). Currently, a 5.0 mm standard planning target volume (PTV) margin is widely used to ensure adequate dose to the tumor.
View Article and Find Full Text PDFSci Rep
December 2024
United States Fish and Wildlife Service, Tulsa, OK, USA.
Abundance estimates inform ungulate management and recovery efforts. Yet effective and affordable estimation techniques remain absent for most ungulates lacking identifiable marks and inhabiting rugged or highly vegetated terrain. Methods using N-mixture models with camera trap imagery form an appealing solution but remain unvalidated.
View Article and Find Full Text PDFJ Pharm Biomed Anal
December 2024
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands; Leiden Network for Personalized Medicine, Leiden, the Netherlands. Electronic address:
Voclosporin is a potent immunosuppressive agent currently approved for treating active lupus nephritis. Based on its potential antiviral activity, it has also been investigated as immunosuppressive agent in an investigator-initiated study in SARS-CoV2 positive kidney transplant recipients. As with many immunosuppressive agents, optimizing dosing regimens to achieve therapeutic efficacy while minimizing toxicity remains a critical challenge in clinical practice.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!